المؤلفون: Mateos, Maria-Victoria, Rodriguez Otero, Paula, Koh, Youngil, Martinez-Lopez, Joaquin, Parmar, Gurdeep, Prince, H. Miles, Quach, Hang, Ribas, Paz, Hermansen, Emil, Hungria, Vania T. M., Kalayoğlu Beşışık, Sevgi, Kim, Jin Seok, Leleu, Xavier, Peceliunas, Valdas, Schjesvold, Fredrik, Sevindik, Ömür Gökmen, Lavrova, Tatiana, Dubin, Franck, Devisme, Christine, Lepine, Lucie, Ghobrial, Irene

مصطلحات موضوعية: 3 Ithaca Study, High-Risk Smoldering Multiple Myeloma, Dexamethasone, Lenalidomide

وصف الملف: application/pdf

العلاقة: Blood; Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı; Mateos, M.-V., Rodriguez Otero, P., Koh, Y., Martinez-Lopez, J., Parmar, G., Prince, H. M. . Ghobrial, I. (2022). Isatuximab in combination with lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma: Updated safety run-in results from the randomized phase 3 ithaca study. American Society of Hematology içinde (7317-7319. ss.). https://dx.doi.org/10.1182/blood-2022-157302Test; https://dx.doi.org/10.1182/blood-2022-157302Test; https://hdl.handle.net/20.500.12511/10630Test; 140; Supplement: 1; 7317; 7319; Q1; 000893230300143

الإتاحة: https://doi.org/20.500.12511/10630Test
https://doi.org/10.1182/blood-2022-157302Test
https://hdl.handle.net/20.500.12511/10630Test

المؤلفون: Maria-Victoria Mateos, Paula Rodriguez Otero, Youngil Koh, Joaquin Martinez-Lopez, Gurdeep Parmar, H. Miles Prince, Hang Quach, Paz Ribas, Emil Hermansen, Vania T.M. Hungria, Sevgi Kalayoglu Besisik, Jin Seok Kim, Xavier Leleu, Valdas Pečeliūnas, Fredrik Schjesvold, Omur G. Sevindik, Tatiana Lavrova, Franck Dubin, Christine Devisme, Lucie Lepine, Sandrine Macé, Mony Morisse, Irene Ghobrial

مصطلحات موضوعية: 3 Ithaca Study, Immunology, Cell Biology, Hematology, Biochemistry, Lenalidomide, High-Risk Smoldering Multiple Myeloma, Dexamethasone

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a625388b7e086ccf704fd1a7a005cf9Test
https://hdl.handle.net/20.500.12511/10630Test

المؤلفون: Janssen Research & Development, LLC

المساهمون: Irene Ghobrial, MD, Sponsor Investigator

المصدر: Immuno-PRISM (PRecision Intervention Smoldering Myeloma): A Randomized Phase II Platform Study of Select Immunotherapies for High-Risk Smoldering Myeloma

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05469893Test

المؤلفون: Janssen, LP

المساهمون: Omar Nadeem, MD, Sponsor Investigator

المصدر: B- PRISM (Precision Intervention Smoldering Myeloma): A Phase II Trial of Combination of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04775550Test

المؤلفون: Pharmacyclics LLC.

المساهمون: Ajai Chari, Associate Professor

المصدر: A Phase 2 Study of the Effect of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib on Disease Response in Patients With High Risk Smoldering Multiple Myeloma

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT02943473Test

المصدر: A Phase 2, Randomized, Blinded, Placebo-controlled, Multicenter Study of Siltuximab (Anti IL 6 Monoclonal Antibody) in Subjects With High-risk Smoldering Multiple Myeloma

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT01484275Test

المؤلفون: Millennium Pharmaceuticals, Inc.

المصدر: Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT02697383Test

Other URLs: https://www.mskcc.orgTest/